308 related articles for article (PubMed ID: 33665773)
1. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
2. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
3. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
4. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
[TBL] [Abstract][Full Text] [Related]
6. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
[TBL] [Abstract][Full Text] [Related]
7. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
[TBL] [Abstract][Full Text] [Related]
8. Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients.
Chen CH; Peng CY; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN
J Infect Dis; 2022 Jun; 225(11):1974-1981. PubMed ID: 34894128
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
10. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
[TBL] [Abstract][Full Text] [Related]
11. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
[TBL] [Abstract][Full Text] [Related]
12. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Kuo MT; Tseng PL; Chou YP; Chang KC; Tsai MC; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
J Gastroenterol Hepatol; 2018 Oct; 33(10):1766-1772. PubMed ID: 29514418
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
Fang HW; Yen YH; Hung CH; Wang JH; Hu TH; Lu SN; Chen CH
Dig Dis Sci; 2022 Jul; 67(7):3402-3411. PubMed ID: 34241753
[TBL] [Abstract][Full Text] [Related]
14. Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients.
Chen YC; Hsu CW; Chien RN
J Med Virol; 2023 Nov; 95(11):e29213. PubMed ID: 37933418
[TBL] [Abstract][Full Text] [Related]
15. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
[TBL] [Abstract][Full Text] [Related]
17. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
Chen CH; Peng CY; Hu TH; Wang JH; Hung CH; Lu SN
Aliment Pharmacol Ther; 2023 Aug; 58(3):334-345. PubMed ID: 37265196
[TBL] [Abstract][Full Text] [Related]
18. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
Hsu YC; Nguyen MH; Mo LR; Wu MS; Yang TH; Chen CC; Tseng CH; Tai CM; Wu CY; Lin JT; Tanaka Y; Chang CY
Aliment Pharmacol Ther; 2019 Jan; 49(1):107-115. PubMed ID: 30450681
[TBL] [Abstract][Full Text] [Related]
19. Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
Lin MJ; Su TH; Liu CJ; Yang HC; Chen CL; Liou JM; Tseng TC; Liu CH; Hong CM; Chen PJ; Kao JH
J Formos Med Assoc; 2023 Jul; 122(7):564-573. PubMed ID: 36872131
[TBL] [Abstract][Full Text] [Related]
20. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]